[New post] Mavacamten for Obstructive Hypertrophic Cardiomyopathy Receives FDA Approval
Conference Alerts posted: " Mavacamten is a first-in-class oral allosteric modulator of cardiac myosin that is used to enhance VO2 and decrease contractile function in patients with obstructive hypertrophic cardiomyopathy. Mavacamten (Camzyos) has been approved by the FDA for th" European Conferences
Mavacamten is a first-in-class oral allosteric modulator of cardiac myosin that is used to enhance VO2 and decrease contractile function in patients with obstructive hypertrophic cardiomyopathy.
Mavacamten (Camzyos) has been approved by the FDA for the treatment of adult patients with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy (oHCM).
Mavacamten is a first-in-class oral allosteric modulator of cardiac myosin that is used to increase VO2 and decrease contractile function in individuals with oHCM, which commonly leads in dynamic left ventricular outflow tract (LVOT) blockage. oHCM thickens the heart walls, making it harder for the heart to expand and fill with blood appropriately. Mavacamten seeks to target the disease's underlying pathogenesis.
In a press release, Milind Desai, MD, MBA, head of the Hypertrophic Cardiomyopathy Center and director of clinical operations at Cleveland Clinic's Heart Vascular & Thoracic Institute, said, "This is a first-in-class drug exclusively for patients living with symptomatic obstructive HCM." "With the FDA's approval, cardiologists in the United States now have a new pharmaceutical alternative for eligible patients that targets the disease's underlying pathophysiology."
2nd International Conference on Heart and Cardiovascular Diseases 2022
Theme: Use Heart to Connect and Harness the power of digital health to improve awareness
According to findings presented at the American College of Cardiology 2022 Scientific Sessions, the EXPLORER-LTE trial demonstrated that treatment with mavacamten improves LVOT gradients, NYHA Class, and N-terminal pro brain natriuretic peptide (NT-proBNP) levels over time. Mavacamten has been shown to diminish cardiac muscle contractility by blocking excessive myosin-actin cross-bridge production, which causes hyper contractility, left ventricular hypertrophy, and decreased compliance.
In a press release, Samit Hirawat, MD, executive vice president and chief medical officer, Global Drug Development, Bristol Myers Squibb, said, "This approval builds on our decades of cardiovascular leadership and demonstrates our steadfast commitment to patients afflicted by cardiovascular disease." "We are excited to deliver this first-of-its-kind drug to patients, which may assist to fill a gap in the symptomatic NYHA class II-III obstructive HCM therapy landscape in the United States.
No comments:
Post a Comment